Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Autism Spectrum Disorder (ASD)

Ketamine for Autism Spectrum Disorder (ASD)

3 papers and 1 clinical trial exploring ketamine as a treatment for autism spectrum disorder (asd).

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
IndicationApproximately 1 in 160 children worldwide.

Autism Spectrum Disorder (ASD)

Research into the use of psychedelics for treating Autism Spectrum Disorder (ASD) is limited but gaining traction, with preliminary studies suggesting potential therapeutic benefits, particularly for associated social anxiety. Notable figures in this emerging field, such as Alicia Danforth and Charles Grob, are advocating for further exploration of psychedelics in ASD treatment.

Full Autism Spectrum Disorder (ASD) profile

Academic Research

3 papers
Paywallmeta

Self-Experiments with Psychoactive Substances: A Historical Perspective

This book chapter (2018) presents a historic overview of self-experimentation with psychoactive substances whose scientific documentation began in the mid-1850s and continuously expanded over the next 125 years while stimulating scientific (and therapeutic) advances and becoming increasingly widespread amongst layperson with the rise of New Psychoactive Substances. While psychologists like William James and Sigmund Freud drew significant inspiration from their drug experiences, other examples may serve as cautionary tales, such as John C. Lilly’s account of ketamine dependence that developed out of self-experimentation.

Published
November 27, 2018
Journal
New Psychoactive Substances
Authors
Passie, T., Brandt, S. D.
Open Accessindividual

A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers

In a retrospective analysis of 274 surviving war‑wounded soldiers from Afghanistan, ketamine administration was not independently associated with development of acute or post‑traumatic stress disorder; multivariable regression identified only acute stress disorder and total number of surgical procedures as independent predictors of PTSD. Although a higher proportion of PTSD cases had received ketamine on unadjusted analysis, injury severity and other covariables accounted for that association.

Published
October 3, 2017
Journal
Anaesthesia
Authors
Mion, G., Masson, J. L., Granier, C., Hoffmann, C.
Open Accessmeta

Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression

This article (2015) examines the advantages and applications of intranasal drug delivery, with a particular focus on the potential of intranasal ketamine for the acute and maintenance therapy of refractory depression. The article contrasts intranasal delivery to oral and sublingual delivery methods, which are less effective with regards to their bioavailability, crossing of the blood-brain-barrier, and rapid onset of drug effects.

Published
January 1, 2015
Journal
Journal of Clinical Psychiatry
Authors
Andrade, C.

Clinical Trials

1 trial
CompletedPhase II

A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

Double-blind, placebo-controlled crossover trial (n=23) assessing oral ketamine given twice daily for 5 days (cohort doses 0.75 mg/kg and 1.5 mg/kg) vs placebo in females aged 6–12 with Rett syndrome.

Started
March 12, 2019
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT03633058

Explore further

Search all Ketamine papers Search all Autism Spectrum Disorder (ASD) trials Full Ketamine profile Full Autism Spectrum Disorder (ASD) profile